The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1061-1065

  Shimabukuro Vornhagen, Alexander ^a   Draube, Andreas ^a   Liebig, Tanja ^a   Popov, Alexey ^a   Von Bergwelt Baildon, Achim Rothe Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Antigen presenting cells; Cd40 activated B cells; Migration; Prostaglandin E 2; T cell stimulation; Tumor immunotherapy

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL MIGRATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE MIGRATION; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SHAPE; CHEMOTAXIS; COCULTURE TECHNIQUES; DINOPROSTONE; HUMANS; MICE; NIH 3T3 CELLS; PHENOTYPE; RECEPTORS, CCR7; RECEPTORS, CXCR4; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84872765615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2215     Document Type: Article

References (44)

1. Rosenberg S, Yang J and Restifo N: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004. (Pubitemid 39273730)
2. Finn OJ: Cancer immunology. N Engl J Med 358: 2704-2715, 2008.
3. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immuno-therapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
4. Palucka K, Ueno H and Banchereau J: Recent developments in cancer vaccines. J Immunol 186: 1325-1331, 2011.
5. Copier J, Dalgleish AG, Britten CM, et al: Improving the efficacy of cancer immunotherapy. Eur J Cancer 45: 1424-1431, 2009.
6. Zou W: Regulatory T cells, tumour immunity and immuno-therapy. Nat Rev Immunol 6: 295-307, 2006.
7. 2. J Immunol 188: 21-28, 2012.
8. Matsuoka T and Narumiya S: The roles of prostanoids in infection and sickness behaviors. J Infect Chemother 14: 270-278, 2008.
9. Sheng KC, Wright MD and Apostolopoulos V: Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem 18: 5507-5518, 2011.
10. Sombroek CC, Stam AG, Masterson AJ, et al: Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168: 4333-4343, 2002. (Pubitemid 34441333)
11. Kolenko V, Rayman P, Roy B, et al: Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood 93: 2308-2318, 1999. (Pubitemid 29153634)
12. 2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology 111: 298-305, 2004. (Pubitemid 38365752)
13. 2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118: 5498-5505, 2011.
14. Krishnamoorthy S and Honn KV: Eicosanoids in tumor progression and metastasis. Subcell Biochem 49: 145-168, 2008.
15. Haas AR, Sun J, Vachani A, et al: Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12: 214-222, 2006. (Pubitemid 43166197)
16. Luft T, Jefford M, Luetjens P, et al: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100: 1362-1372, 2002. (Pubitemid 34864293)
17. 2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100: 1354-1361, 2002. (Pubitemid 34864292)
18. Braun D, Longman RS and Albert ML: A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2375-2381, 2005. (Pubitemid 41510810)
19. 2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237, 2006. (Pubitemid 43990633)
20. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, et al: PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116: 1454-1459, 2010.
21. Martin F and Chan AC: B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24: 467-496, 2006.
22. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al: The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114: 4919-4927, 2009.
23. Mason NJ, Coughlin CM, Overley B, et al: RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 15: 955-965, 2008. (Pubitemid 351865752)
24. Sorenmo KU, Krick E, Coughlin CM, et al: CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One 6: e24167, 2011.
25. Von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al: CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 107: 2786-2789, 2006.
26. Wiesner M, Zentz C, Mayr C, et al: Conditional immortalization of human B cells by CD40 ligation. PLoS One 3: e1464, 2008.
27. Kondo E, Gryschok L, Klein-Gonzalez N, et al: CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol 155: 249-256, 2009.
28. Liebig TM, Fiedler A, Zoghi S, et al: Generation of human CD40-activated B cells. J Vis Exp pii: 1373, 2009
29. Popov A, Driesen J, Abdullah Z, et al: Infection of myeloid dendritic cells with Listeria monocytogenes leads to the suppression of T cell function by multiple inhibitory mechanisms. J Immunol 181: 4976-4988, 2008.
30. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 66: 1114-1122, 2006. (Pubitemid 43165980)
31. 2 and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α. Immunology 128: 439-450, 2009
32. Herfs M, Herman L, Hubert P, et al: High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother 58: 603-614, 2009
33. Muthuswamy R, Urban J, Lee JJ, et al: Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 68: 5972-5978, 2008.
34. 2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol 82: 1106-1114, 2007 (Pubitemid 350133506)
35. Wobser M, Voigt H, Houben R, et al: Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 56: 1017-1024, 2007 (Pubitemid 46675300)
36. Forster R, Schubel A, Breitfield D, et al: CCR7 coordinates the primary immune response by establishing functional micro-environments in secondary lymphoid organs. Cell 99: 23-33, 1999 (Pubitemid 29468627)
37. Ohl L, Mohaupt M, Czeloth N, et al: CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21: 279-288, 2004 (Pubitemid 39094056)
38. Kabashima K, Shiraishi N, Sugita K, et al: CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol 171: 1249-1257, 2007 (Pubitemid 47582898)
39. Schultze JL, Grabbe S and von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 25: 659-664, 2004 (Pubitemid 39457979)
40. Kim SK, Nguyen Pham TN, Nguyen Hoang TM, et al: Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol 88: 1113-1123, 2009
41. 4 receptor subtypes. J Leukoc Biol 73: 756-763, 2003. (Pubitemid 38040454)
42. 2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176: 966-973, 2006. (Pubitemid 43099695)
43. 4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA 93: 10978-10983, 1996. (Pubitemid 26333103)
44. 2 pathway augments activation-induced cytosine deaminase expression within replicating human B cells. J Immunol 185: 5300-5314, 2010.